9th Annual Conference Of The British HIV Association [BHIVA]


24 – 26 April 2003, University of Manchester
Institute of Science & Technology (UMIST)
Manchester


Print this article
[TITLE:] THE SUCCESS OF TENOFOVIR (TNF) AND DIDANOSINE (DDI) WHEN DOSED TOGETHER USING LOW-DOSE DIDANOSINE 250 MG

[AUTHOR(S):] M Tung, A Pathmanathan, J Chandra, M Bower, BG Gazzard and MR Nelson
Chelsea and Westminster Hospital, London, UK

BHIVA Conf 2003 Apr 24-26;9:O8


AIM: Clinical trials have shown that TNF when co-administered with ddI at 400 mg increases ddI plasma concentrations >60%, raising concerns over toxicity. To minimise this interaction, ddI at 250 mg coadministered with TNF and taken simultaneously has been suggested.

METHODS: Retrospective study of all patients commenced on antiretroviral regimens containing TNF with either 400 or 250 mg ddI. Viral load at the start of the regimen and time to sustained undetectable HIV-1 RNA (<400 copies/ml) were noted. All patients who had to switch regimens due to side effects or experienced virological failure were documented.

RESULTS: Data are available on 24 patients who commenced regimens with TNF and 250 mg ddI, and 63 patients on tenofovir and 400 mg ddI. Four patients were treatment-naïve. On-treatment analysis demonstrated virological suppression to <400 copies/ml by 89% of patients on ddI 250, and 92% on ddI 400 at 3 months. At 6 months, 100% on ddI 250 and 91% on ddI 400 remain undetectable. By intention-totreat analysis, virological suppression was achieved by 84% on ddI 250 and 92% on ddI 400 at 3 months, 67% on ddI 250 and 84% on ddI 400 at 6 months. In a second cohort of patients with a viral load <400 copies/ml on, or switching to, TNF plus ddI 250 (n=78) or ddI 400 (n=112), time from below the level of detection to treatment failure between the two groups was not statistically different (P=0.40), showing that ddI 250 is as efficacious as ddI 400.

CONCLUSIONS: Our clinical cohort has shown that TNF with ddI at 250 mg compares favourably with ddI at 400 mg. Thus low-dose ddI at 250 mg plus TNF is an effective combination.

PRESENTING AUTHOR: M Tung

Download Presentation

030424
O8

Copyright © 2003 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD